

**In the Claims**

1-100. (Cancelled)

101. (Currently amended) A method for treating a subject for ~~asthma, allergic rhinitis, atopic eczema, dermatitis, urticaria, or hives~~ an allergic or hypersensitivity condition comprising mucosally administering to the subject an effective amount of an agent wherein the agent is selected from the group consisting of Etx, Ctx, EtxB, and CtxB that bind to GM1 wherein the agent is co-administered with an allergen or antigen and is not coupled to said allergen or antigen.

102. (Currently amended) The method according to claim ~~404~~ 115 wherein the method is a method of treating said subject for asthma.

103. (Currently amended) The method according to claim ~~404~~ 115 wherein the method is a method of treating said subject for allergic rhinitis.

104. (Currently amended) The method according to claim 101 wherein the agent is administered ~~mucosally, intravenously, intramuscularly or subcutaneously~~ intranasally.

105. (Currently amended) A method for treating a subject for ~~asthma, allergic rhinitis, atopic eczema, dermatitis, urticaria, or hives~~ an allergic or hypersensitivity condition comprising mucosally administering to the subject an effective amount of EtxB that binds to GM1 wherein the EtxB is co-administered with an allergen or antigen and is not coupled to said allergen or antigen.

106. (Currently amended) The method according to claim ~~405~~ 116 wherein the method is a method of treating said subject for asthma.

107. (Currently amended) The method according to claim 405 116 wherein the method is a method of treating said subject for allergic rhinitis.

108. (Cancelled).

109. (Currently amended) A method for treating a subject for asthma comprising mucosally administering to the subject an effective amount of an agent wherein the agent is EtxB that binds to GM1.

110. (Currently amended) The method according to claim 109 wherein the agent is administered ~~mucosally~~ intranasally.

111. (Currently amended) A method for treating a subject for asthma, allergic rhinitis, atopic eczema, dermatitis, urticaria, or hives comprising mucosally administering to the subject an effective amount of an agent wherein the agent is EtxB that binds to GM1.

112. (Previously presented) The method according to claim 111 wherein the method is a method of treating said subject for asthma.

113. (Previously presented) The method according to claim 111 wherein the method is a method of treating said subject for allergic rhinitis.

114. (Cancelled).

115. (New) The method according to claim 101 wherein the method is a method of treating said subject for asthma, allergic rhinitis, atopic eczema, dermatitis, urticaria, or hives.

116. (New) The method according to claim 105 wherein the method is a method of treating said subject for asthma, allergic rhinitis, atopic eczema, dermatitis, urticaria, or hives.

117 (New) The method according to claim 101 wherein the hypersensitivity condition is contact sensitivity.

118 (New) The method according to claim 105 wherein the hypersensitivity condition is contact sensitivity.

119. (New) The method according to claim 117 wherein the hypersensitivity condition is contact sensitivity induced by plant poison ivy.

120. (New) The method according to claim 118 wherein the hypersensitivity condition is contact sensitivity induced by plant poison ivy.

121. (New) A method for treating a subject for an allergic or hypersensitivity condition comprising administering to the subject an effective amount of EtxB that binds to GM1 wherein the EtxB is co-administered with an allergen or antigen and is not coupled to said allergen or antigen.

122. (New) The method according to claim 121 wherein the agent is administered mucosally, intravenously, intramuscularly or subcutaneously.

123. (New) The method according to claim 122 wherein the method is a method of treating said subject for asthma, allergic rhinitis, atopic eczema, dermatitis, urticaria, or hives.

Serial No. 09/600,060  
Amendment Accompanying RCE  
and Response to Final Office Action  
Page 6

124 (New) The method according to claim 122 wherein the hypersensitivity condition is contact sensitivity.